Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 148 Publications

25 Customer Reviews

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  • HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MVPDfZRwfG:6aXOgRZN{[Xl? MknSOVAh|ryP M3K4U|Q5KGh? NFvOdY5FVVOR NGX3dnlMcWyuczDj[YxteyCkeTDtc5JmKHSqYX6gPVkm NGPzcIwyODR7OU[0Ny=>
OVCA 429 MWLGeY5kfGmxbjDBd5NigQ>? MX2zNFAhdk1? NIq4[mY1QCCq Mk[0SG1UVw>? NY\aeFF4TGm|coXweJMhcW62YXP0JI12dHSrY3XscJVt[XJidIXtc5Ihe3CqZYLvbYR{ M1ToWlExQTl7N{[2
RPMI8226 M{n5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDX[|EyODBibl2= MV:0PEBp NYi3Zml[TE2VTx?= NXTNW|l4UUN3ME2zNEBvVQ>? MkLyNVE{ODZ2OEm=
Dox40 M{jGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW1S5QyODBibl2= NHG5UWI1QCCq NGrF[JFFVVOR MWrJR|UxRTRyIH7N MoTnNVE{ODZ2OEm=
MR20 M{PkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXqxNFAhdk1? NHuwd|I1QCCq NXnNcWxvTE2VTx?= NW\YellSUUN3ME2yNEBvVQ>? M1LNWFEyOzB4NEi5
LR5 NVr4OWxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVqyZpdROTByIH7N NVnYT3ZjPDhiaB?= NULueVdWTE2VTx?= NIWz[|BKSzVyPUKwJI5O MVyxNVMxPjR6OR?=
U266 Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfmOXEyODBibl2= NFH0XGw1QCCq NXryenNwTE2VTx?= NHuzfnBKSzVyPUOgcm0> MmPUNVE{ODZ2OEm=
IM-9 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXlNVAxKG6P NWTJdoZOPDhiaB?= NUHVXlIzTE2VTx?= MkS4TWM2OD14IH7N NETxfmcyOTNyNkS4PS=>
Hs Sultan MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnWNVAxKG6P NX:wSol5PDhiaB?= Mkj5SG1UVw>? NF34eYdKSzVyPUKwJI5O MWGxNVMxPjR6OR?=
PAM-LY2 NEnqcHpHfW6ldHnvckBCe3OjeR?= MYSxNFAhdk1? NUfsPZlQOTJiaB?= NWCzVJBUTE2VTx?= NXjyPZNmUW6qaXLpeJMhVkZvzsrCJIFkfGm4YYTpc44> M{DNe|EyOzVyOUGz
PAM 212 Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYewSIlGOTByIH7N M{\0UVczKGh? NXroTGRLTE2VTx?= M2XGXmlvcGmkaYTzJINmdGxidnnhZoltcXS7 NFLJUJUyOTN3MEmxNy=>
PAM-LY2 NE[5UXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCxNFAhdk1? NGTBbII4OiCq M1TGS2ROW09? NF\TOHNKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= M4TZN|EyOzVyOUGz
B4B8 Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIS5TmkyODBibl2= M1\iSlczKGh? MlPiSG1UVw>? M4n4UmlvcGmkaYTzJINmdGxidnnhZoltcXS7 MorhNVE{PTB7MUO=
B7E3 NIXMeZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LtOFExOCCwTR?= MX23NkBp NELsdIVFVVOR MYPJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MnTTNVE{PTB7MUO=
UM-SCC-9 M{X6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLEcZVLOTByIH7N NYPYOGJRPzJiaB?= NYrhS5JITE2VTx?= M{P2eWlvcGmkaYTzJINmdGxidnnhZoltcXS7 MWWxNVM2ODlzMx?=
UM-SCC-11B MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[xNFAhdk1? M4\IPFczKGh? NFHwNY5FVVOR NEexblNKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= Ml72NVE{PTB7MUO=
H460 NG\IblFHfW6ldHnvckBCe3OjeR?= NICzdG4yOCEQvF2= M2jyRVI1KGh? MULEUXNQ NUnOWolNUW6mdXPld{BD[2xvMjDwbI9{eGixconsZZRqd25iYX7kJINt\WG4YXflJINwenKnbHH0[YQhf2m2aDDHNk1OKHCqYYPlJIFzemW|dB?= NXP4b414OTJ2OUKxNVc>
U266 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUS1NFAhdmdxbXy= M3HSfVQ5KGh? MX7EUXNQ MkTFTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NH\qXmoyOjZ|MU[xPS=>
ARH77 NXrD[lVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M323UlUxOCCwZz;tcC=> MVu0PEBp M2C4eWROW09? MXLJcohq[mm2czDj[YxtKGe{b4f0bC=> NFSycJcyOjZ|MU[xPS=>
WAD-1 NX;XRpR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHe0WJE2ODBibnevcYw> MoL2OFghcA>? MUHEUXNQ NFPndZlKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MVSxNlY{OTZzOR?=
U266/LR7 NEPldmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\XTXM2ODBibnevcYw> MmDqOFghcA>? MnP6SG1UVw>? MWTJcohq[mm2czDj[YxtKGe{b4f0bC=> MkDWNVI3OzF4MUm=
U266/dox4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXGT|E2ODBibnevcYw> M1rWOVQ5KGh? M3n6fmROW09? MX7Jcohq[mm2czDj[YxtKGe{b4f0bC=> M1n6UFEzPjNzNkG5
RPMI8226/LR5 M3XmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrPd5Y2ODBibnevcYw> MVm0PEBp NYT4VGtiTE2VTx?= MknFTY5pcWKrdIOgZ4VtdCCpcn;3eIg> Mn7FNVI3OzF4MUm=
H460 M4jtT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHLNVAh|ryP NEPLN4s4OiCq MknBSG1UVw>? M1PmW2lEPTB;MUCwJI5O MkCwNVI3OzF4MkC=
H358 MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[xNEDPxE1? MniwO|IhcA>? NWLyZmx{TE2VTx?= MUfJR|UxRTdyIH7N NHracZQyOjZ|MU[yNC=>
H322 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF20NJoyOCEQvF2= NYnMWpZCPzJiaB?= NVXqO5RYTE2VTx?= NFi3boNKSzVyPU[yNEBvVQ>? M2\qfFEzPjNzNkKw
H460 NE\hdlNHfW6ldHnvckBCe3OjeR?= MkfpNVAxKG6P NInG[5IzPCCq Mkf6SG1UVw>? M2j0NGlv\HWlZYOgS|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO|ZX3icJku\Gm|YYPz[Y1jdHl? NFHTUo4yOjZ|MU[yNC=>
LNCap-Pro5 M{TLbmZ2dmO2aX;uJGF{e2G7 M2PEflEh|ryP M1i0flQhcA>? MV\EUXNQ Moq0V5Ri[mmuaYrld{BxPTN? M{HBSVE1PjF{NUOy
T29 NEm1XpZCeG:ydH;zbZMhSXO|YYm= NV[3OZNEPTBibl2= NVS0WWxFPDhiaDC= MmfaSG1UVw>? MWnJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NEfjVG4yPjd5OEG3PS=>
T29Kt1 NFrUUYJCeG:ydH;zbZMhSXO|YYm= NVTMUIlCPTBibl2= MWK0PEBpKA>? NVrFS|E{TE2VTx?= MYfJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MXKxOlc4QDF5OR?=
HCT116 M4X4WmFxd3C2b4Ppd{BCe3OjeR?= M1L2d|UxKG6P NWrme2hLPDhiaDC= NHjOTpNFVVOR NFW4NlNKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NUPidVhuOTZ5N{ixO|k>
HKe-3 MYrBdI9xfG:|aYOgRZN{[Xl? NWL5VnBSPTBibl2= MlKyOFghcCB? M1\2V2ROW09? M2\UcWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NGjlZ24yPjd5OEG3PS=>
NB-1691 NIezZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDDNUDPxE1? MWS3NkBp MWnJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hPSV? MoS2NVc3QDl4OES=
CHLA-255 NEexZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i3OlEh|ryP M4PWeVczKGh? NUni[mZ6UW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEKl M4rlXFE4Pjh7Nki0
SK-N-AS MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PmNVEh|ryP MU[3NkBp Mm\sTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDFyJR?= Mn6yNVc3QDl4OES=
NB-1691 NXzCPIJjTnWwY4Tpc44hSXO|YYm= Moj1NVAhdk1? NVq2VmZDOjRiaB?= M{\nbXNq\26rZnnjZY51dHlicnXkeYNmeyClZXzsd{BqdiC2aHWgS|AwTzFicHjhd4U> NYTkcWlpOTd4OEm2PFQ>
CHLA-255 NYDFRYk6TnWwY4Tpc44hSXO|YYm= Ml7RNVAhdk1? MUmyOEBp NFPabmZOd2Snc4TsfUBz\WS3Y3XzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZR?= MV6xO|Y5QTZ6NB?=
RPMI 8226 M{m5[2Z2dmO2aX;uJGF{e2G7 MojCNlAhdk1? NVfhPFZiQCCq NXPnNY1YW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? MUmxPVQ{PjB3MB?=
MM.1S NXOyZpJiTnWwY4Tpc44hSXO|YYm= NIfNb|gzOCCwTR?= NH;KN2I5KGh? MUnTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> M2[wZlE6PDN4MEWw
U266 M2X4RmZ2dmO2aX;uJGF{e2G7 MnjHNlAhdk1? NYqw[4tSQCCq M{PGUnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MVexPVQ{PjB3MB?=
OPM1 NUP0ZZhVTnWwY4Tpc44hSXO|YYm= MW[yNEBvVQ>? M17BN|ghcA>? MnTrV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> M17JbVE6PDN4MEWw
INA6 NHLUPXlHfW6ldHnvckBCe3OjeR?= MUSyNEBvVQ>? MVe4JIg> NFzjbmlUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? Ml3NNVk1OzZyNUC=
OPM2 MmPLSpVv[3Srb36gRZN{[Xl? MXKyNEBvVQ>? MonhPEBp NUjnSZk6W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NWDmPZNiOTl2M{[wOVA>
RPMI 8226 NWDyc3cyTnWwY4Tpc44hSXO|YYm= NHTyT|MzOCCwTR?= NWDnSXQ6QCCq MXfJcoR2[2W|IFTORUB{gW62aHXzbZM> NWjHUnA1OTl2M{[wOVA>
BaF/3 NX\hVXdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDW[lcyODBibl2= M1G3Z|Q5KGh? NYTr[ZJYUUN3ME22MlIhdk1? NHPiZ4ozODNyNU[5Ni=>
BaF/3-p210 M12zeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:xNFAhdk1? MUW0PEBp Mo\CTWM2OD12Lkegcm0> NVzROop7OjB|MEW2PVI>
TCC-S NFnKcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXW[msyODBibl2= M{SwdlQ5KGh? M2\SbWlEPTB;Mj64JI5O NESzS2czODNyNU[5Ni=>
BaF/3 MnywSpVv[3Srb36gRZN{[Xl? M1jDOlYhdk1? MlLSOFghcA>? NWnuZox7UW6mdXPld{BiKGe{ZXH0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 MX[yNFMxPTZ7Mh?=
BaF/3-p210 MXrGeY5kfGmxbjDBd5NigQ>? MnjlOkBvVQ>? NWPi[2NTPDhiaB?= MYLJcoR2[2W|IHGgd4xq\2i2IFexJINmdGxvY4njcIUh[XK{ZYP0 M1;4ZVIxOzB3Nkmy
BaF/3-p210 MYPGeY5kfGmxbjDBd5NigQ>? NUjpVoR6PiCwTR?= NXHkc5pLOjRiaB?= MWjS[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gZY5lKHSqZTDhZ5Rqfmm2eTDv[kBT[g>? MVuyNFMxPTZ7Mh?=
Raji M3TYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G3ZlEh|ryP NUHJWXF{OjRiaB?= NV[xSJhmWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MYSyNVE4ODl6OB?=
LCL-1 M{frXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKxJO69VQ>? M2HqS|I1KGh? M1f2TnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MmnQNlEyPzB7OEi=
LCL-2 MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHTNUDPxE1? NUfSOmVGOjRiaB?= M{TKTnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M13uSlIyOTdyOUi4
BJAB NFjYNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHYNmEyKM7:TR?= MYOyOEBp NU\zOplzWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NGPmXlYzOTF5MEm4PC=>
SNT-13 NELOdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHH3VYwyKM7:TR?= M1yzOFI1KGh? NWP5VZVzWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MlPPNlEyPzB7OEi=
SNT-16 Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCxJO69VQ>? M2C3SVI1KGh? M1PrbHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NHG3d5czOTF5MEm4PC=>
Jurkat NHPLOHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fDUVEh|ryP NFrqOWMzPCCq NYLPRpFpWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg Ml;CNlEyPzB7OEi=
KAI-3 NWK2PHk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWixJO69VQ>? MV:yOEBp NHnXWlRT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MnTDNlEyPzB7OEi=
SNK-6 NYnZWpVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXEVIwyKM7:TR?= Mk[5NlQhcA>? M1LUSHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MoXNNlEyPzB7OEi=
KHYG-1 NUnzbIVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2xJO69VQ>? MUKyOEBp M{H5dHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MVKyNVE4ODl6OB?=
SNT-16 NEDpXnNCeG:ydH;zbZMhSXO|YYm= MVOxJO69VQ>? M1LKOVYhcA>? MkLrTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MXeyNVE4ODl6OB?=
Jurkat MXTBdI9xfG:|aYOgRZN{[Xl? M4jqfVEh|ryP NGmwfFY3KGh? MWTJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NIXmc|EzOTF5MEm4PC=>
KAI-3 Ml61RZBweHSxc3nzJGF{e2G7 NIPSXJgyKM7:TR?= NITVO2Y3KGh? NHnkfVFKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M3rnN|IyOTdyOUi4
KHYG-1 Mk\nRZBweHSxc3nzJGF{e2G7 NYO2VZZMOSEQvF2= NEixb5Y3KGh? Mn\LTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M4LP[|IyOTdyOUi4
SNT-13 NWLDO414SW62aY\pdoFtKEG|c3H5 M{LZRVEh|ryP NYPFSYhDOjRiaB?= MmrXTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX MUiyNVE4ODl6OB?=
SNT-16 MkfPRY51cX[rcnHsJGF{e2G7 NFjBTosyKM7:TR?= NYrUVmlbOjRiaB?= MmnPTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX MWOyNVE4ODl6OB?=
KAI-3 NHHwb|RCdnSrdnnyZYwhSXO|YYm= MnG5NUDPxE1? MnnmNlQhcA>? MV;JcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> NIW0b3MzOTF5MEm4PC=>
SNK-6 M4DRXGFvfGm4aYLhcEBCe3OjeR?= NYHRO2NvOSEQvF2= M2Lh[lI1KGh? NX3PWZNOUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY M{ThVFIyOTdyOUi4
RAW 264.7 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUn6PZpKOTByIH7N NWHGOms6PDhiaB?= NU\kbVd7WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MoHSNlI1OjdzNUS=
A375 MYPBdI9xfG:|aYOgRZN{[Xl? MVSxNEBvVQ>? M2HvVVI1KGh? NUOwSmIxUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M3TvSVI{ODd7MEiz
BLM NXzFVowzSXCxcITvd4l{KEG|c3H5 M4WwSlExKG6P NV;HPVY{OjRiaB?= MnjNTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NUK2VoNmOjNyN{mwPFM>
A375 NILGO|VCfXSxcHjh[5khSXO|YYm= NF\0ZmoyOCCwTR?= M4fmfVEzKGh? M3[2VGlv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz NV\hSJk2OjNyN{mwPFM>
BLM NXrGfJg4SXW2b4DoZYd6KEG|c3H5 M1S1dVExKG6P MUexNkBp MlTXTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= NFHjO3czOzB5OUC4Ny=>
H1299 MoDYRZBweHSxc3nzJGF{e2G7 MYm4NEBvVQ>? M3TBbVI1KGh? M3\CRmROW09? NWj5cXZDW2Wwc3n0bZpmeyCQU1PMR{Bk\WyuczD0c{BOW0NvZHXybZZm\CCrQ{mtbY5lfWOnZDDhdI9xfG:|aYO= MYmyOVMzOzZ7Mx?=
Hut-78 NV3kXlZXTnWwY4Tpc44hSXO|YYm= NH;EXpgyODBibl2= NH2xXpozPCCq NXX1VWx4TE2VTx?= MknqSI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOCCneIDy[ZN{cW:w MYKyOVY5OTN|NR?=
H9 M2GxTmZ2dmO2aX;uJGF{e2G7 NG\4WoMyODBibl2= MoO2NlQhcA>? NHywVVRFVVOR M{fLZWRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTFiZYjwdoV{e2mxbh?= MViyOVY5OTN|NR?=
HH MmTHSpVv[3Srb36gRZN{[Xl? M4Tpc|ExOCCwTR?= MkLXNlQhcA>? M33iSmROW09? M3XyToRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTJiZYjwdoV{e2mxbh?= MUiyOVY5OTN|NR?=
Hut-78 NGHORXhOcWe{YYTpc44hSXO|YYm= M2HFWlExOCCwTR?= MnW4NlQhcA>? NYLafHAxTE2VTx?= MnTmVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlyJR?= MYCyOVY5OTN|NR?=
HH NX7uXIlpVWmpcnH0bY9vKEG|c3H5 NVzMd5cyOTByIH7N NXnuS2l5OjRiaB?= M2TaTGROW09? NWrR[m5{WmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mxKS=> MUmyOVY5OTN|NR?=
U937 MofRSpVv[3Srb36gRZN{[Xl? MnX6NVAxKG6P NV;aO5h4PiCq MkjjTY5lfWOnczDJUE05KGW6cILld5Nqd25iaX6gUHBUNXO2aX31cIF1\WRiVUmzO{Bu[WO{b4DoZYdmew>? NV7wO5VkOjV5OUG0O|c>
human PBMC M4nUeGZ2dmO2aX;uJGF{e2G7 NF\TeIYyODBibl2= NW\VOm8zOjRiaB?= MorGTY5lfWOnczDJUE05KHKnbHXhd4U> M1fxVlI2PzlzNEe3
ES6 M4DVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XYdmlEPTB;MD6wNFIyKG6P NFi5cYFUSU6JRWK=
SK-UT-1 NXfXbGZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[0TohKSzVyPUCuNVY{KG6P MXzTRW5ITVJ?
SH-4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XZXWlEPTB;MD6xO|Mhdk1? M1LZOnNCVkeHUh?=
TE-9 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HUfWlEPTB;MD6xPFIhdk1? NXvXZnRRW0GQR1XS
A253 MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjjV2hTUUN3ME2wMlIxQCCwTR?= MXjTRW5ITVJ?
no-10 NW\YNWpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3nTWM2OD1yLkKxJI5O MmfFV2FPT0WU
MMAC-SF NInsO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PtWmlEPTB;MD6yNVYhdk1? MnW0V2FPT0WU
A101D M3XlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPmTWM2OD1yLkKyOUBvVQ>? NEKxSoxUSU6JRWK=
NTERA-S-cl-D1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMkSzJI5O MnKzV2FPT0WU
8-MG-BA NF32OFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMkWgcm0> NILiOIJUSU6JRWK=
KNS-42 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XqOGlEPTB;MD6yOVghdk1? Mo\GV2FPT0WU
LXF-289 NGfUfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XKNGlEPTB;MD6yOlkhdk1? NUnoVotHW0GQR1XS
OVCAR-4 NGH2cGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMki5JI5O NH;IR5VUSU6JRWK=
LOUCY NVrqWJVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkj5TWM2OD1yLkK5N{BvVQ>? NV32WJhsW0GQR1XS
BB65-RCC Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETzUJFKSzVyPUCuN|A1KG6P M{nBbnNCVkeHUh?=
D-542MG M{nMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP1TWM2OD1yLkOyPUBvVQ>? M3nGNXNCVkeHUh?=
ONS-76 M2j6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW5T|NKSzVyPUCuN|Mhdk1? M4[3[XNCVkeHUh?=
BB30-HNC NWf2WId1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXkTWM2OD1yLkOzOUBvVQ>? MXTTRW5ITVJ?
KS-1 M1XvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwM{Sgcm0> NXfBNlBJW0GQR1XS
A388 M2fsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjkeo06UUN3ME2wMlM2PiCwTR?= MWTTRW5ITVJ?
ES8 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr6V25KSzVyPUCuOEBvVQ>? NIT2TodUSU6JRWK=
MZ2-MEL MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHRTWM2OD1yLkSwO{BvVQ>? MUfTRW5ITVJ?
HCC2998 NHLvUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwNEGyJI5O NEXwdGpUSU6JRWK=
D-247MG NYi0R5F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H6PWlEPTB;MD60NVMhdk1? MoeyV2FPT0WU
ACN NYHQ[Yk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLSTWM2OD1yLkSxO{BvVQ>? MYjTRW5ITVJ?
LB2518-MEL NXn3NW92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvTTWM2OD1yLkSyOUBvVQ>? NH2wcW1USU6JRWK=
ES1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwNEOgcm0> NIe5UHNUSU6JRWK=
HCE-T Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkX5TWM2OD1yLkSzPUBvVQ>? MWfTRW5ITVJ?
OS-RC-2 M2rVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTwXVZ2UUN3ME2wMlQ1KG6P MoTSV2FPT0WU
MFH-ino MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrkTWM2OD1yLkS0N{BvVQ>? MkDTV2FPT0WU
OCUB-M NELNbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\6TWM2OD1yLkS0O{BvVQ>? MYjTRW5ITVJ?
CP66-MEL MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\ETWM2OD1yLkS3N{BvVQ>? MkDiV2FPT0WU
LB771-HNC M2DrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwNEe0JI5O NYi5OG5zW0GQR1XS
DSH1 M3;ZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7oW|k1UUN3ME2wMlQ5KG6P MXTTRW5ITVJ?
HUTU-80 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj1d4tyUUN3ME2wMlU{OyCwTR?= MkjxV2FPT0WU
CESS M3XscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XPNWlEPTB;MD61N|ghdk1? NG\hbHBUSU6JRWK=
NCI-H747 NWnhb|R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHTTWM2OD1yLkWzPUBvVQ>? MmnLV2FPT0WU
HT-144 NETIPXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ezR2lEPTB;MD61O|Yhdk1? NU\wbFRYW0GQR1XS
COLO-829 M1H1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn6wTWM2OD1yLk[xOEBvVQ>? NYTYNnZjW0GQR1XS
A4-Fuk MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwNkKzJI5O MUDTRW5ITVJ?
GI-ME-N NIHzPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXeycXU5UUN3ME2wMlY{PCCwTR?= M4js[XNCVkeHUh?=
LB831-BLC NFnOcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TKeGlEPTB;MD62OFEhdk1? MVXTRW5ITVJ?
HOP-62 NGr4OpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\CWotKSzVyPUCuOlQ4KG6P MUXTRW5ITVJ?
BB49-HNC MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rUcmlEPTB;MD62OVIhdk1? M{H2OXNCVkeHUh?=
D-336MG NUT5NIFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL1TWM2OD1yLk[1O{BvVQ>? NIe3eVNUSU6JRWK=
TK10 MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDBd|JKSzVyPUCuOlc6KG6P NX3j[GFbW0GQR1XS
Ramos-2G6-4C10 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jFS2lEPTB;MD62PVMhdk1? MX7TRW5ITVJ?
LB373-MEL-D M1TOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe1bnVvUUN3ME2wMlchdk1? M2\EVHNCVkeHUh?=
SF126 M{Swe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe2PHdoUUN3ME2wMlcxOSCwTR?= MkH2V2FPT0WU
UACC-257 NH7PWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGniXFRKSzVyPUCuO|Ehdk1? M{PobnNCVkeHUh?=
KINGS-1 MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\JTWM2OD1yLkeyNkBvVQ>? NEC5UZNUSU6JRWK=
LS-513 M3vaVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmiwTWM2OD1yLkezPUBvVQ>? M1LZdHNCVkeHUh?=
GI-1 NVj5ZZlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;5OmlEPTB;MD63OlQhdk1? M4HYb3NCVkeHUh?=
ES7 NEfrSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:xVFBKSzVyPUCuO|Y3KG6P NVXUc5dqW0GQR1XS
LB2241-RCC NFnvd|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwOEC0JI5O MVjTRW5ITVJ?
D-263MG MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvH[ZJKSzVyPUCuPFA4KG6P NHezeIpUSU6JRWK=
SW684 NXn5d2ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn3TWM2OD1yLkiyNUBvVQ>? MX;TRW5ITVJ?
ML-2 NX75[3M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwOEKxJI5O NHmwUGVUSU6JRWK=
SK-LMS-1 MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwOEW0JI5O MWTTRW5ITVJ?
TE-5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljBTWM2OD1yLki2OUBvVQ>? NHfwSpFUSU6JRWK=
QIMR-WIL M4Hafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfVTWM2OD1yLki4PUBvVQ>? Mn:xV2FPT0WU
NCI-H1355 NXrDVlNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XVUmlEPTB;MD64PVUhdk1? MXrTRW5ITVJ?
SNB75 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTPbIpKUUN3ME2wMlkyOiCwTR?= MXrTRW5ITVJ?
RXF393 M4fSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;4ZmlEPTB;MD65NVQhdk1? MonvV2FPT0WU
IST-MEL1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHju[GxKSzVyPUCuPVE4KG6P Mn:wV2FPT0WU
SF268 Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwOUKzJI5O NIHSR4pUSU6JRWK=
KALS-1 MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{OzXWlEPTB;MD65NlUhdk1? Mn\0V2FPT0WU
HC-1 M1Pzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUX0dXBUUUN3ME2wMlk4PSCwTR?= M3ziSXNCVkeHUh?=
SW872 NELWNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPBTWM2OD1yLkm5OkBvVQ>? M3u2SHNCVkeHUh?=
PSN1 MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFwMEGgcm0> NV25VnJoW0GQR1XS
TE-1 NGixU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH4OWpKSzVyPUGuNFMhdk1? NETaZ|dUSU6JRWK=
TE-10 NUW1TlZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnziTWM2OD1zLkCzJI5O M17ldXNCVkeHUh?=
RKO MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFwME[gcm0> MoHLV2FPT0WU
LC-2-ad MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFwMEigcm0> NFjSUWdUSU6JRWK=
SK-MM-2 NWrITWxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTre2VZUUN3ME2xMlA6KG6P MVzTRW5ITVJ?
VA-ES-BJ NYn3d2lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFwMEmgcm0> NGm1eHNUSU6JRWK=
MZ7-mel NI\ZWpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPDVol6UUN3ME2xMlA6KG6P M1[2SXNCVkeHUh?=
D-392MG NXP5OIEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwMTDuUS=> MkT6V2FPT0WU
CCRF-CEM NWDsUXFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwMUOgcm0> NGnMdoJUSU6JRWK=
EM-2 M4Hzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PZbWlEPTB;MT6xOkBvVQ>? NFrxOlhUSU6JRWK=
HAL-01 Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLF[FRKSzVyPUGuNVghdk1? MYnTRW5ITVJ?
TE-8 Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;lO2RKSzVyPUGuNVkhdk1? NUTkdYtbW0GQR1XS
NCI-H1882 MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nGZ2lEPTB;MT6yJI5O MXrTRW5ITVJ?
Daudi MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfTUXBKSzVyPUGuNlIhdk1? MorOV2FPT0WU
BL-41 NXjYbYdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjpTWM2OD1zLkK1JI5O NYTscXI5W0GQR1XS
SR MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwMkWgcm0> NF;kR2FUSU6JRWK=
KM12 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml23TWM2OD1zLkK3JI5O NUTke2VvW0GQR1XS
K5 MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\UPVU3UUN3ME2xMlI5KG6P M2DEdnNCVkeHUh?=
A3-KAW Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[wZ4p5UUN3ME2xMlI5KG6P NWXIVZYzW0GQR1XS
CMK MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnDTWM2OD1zLkK5JI5O NX3aWZBlW0GQR1XS
Calu-6 M4KwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXjb|hvUUN3ME2xMlI6KG6P NEnBb5dUSU6JRWK=
IST-SL2 M2m3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH6V3JiUUN3ME2xMlMyKG6P NF;rfGtUSU6JRWK=
OPM-2 NFrjdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nTS2lEPTB;MT6zN{BvVQ>? Mnm2V2FPT0WU
DU-4475 M17RbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\UbmlEPTB;MT6zOkBvVQ>? NUDrTIl7W0GQR1XS
ECC12 NXHyNYxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLRcnhKSzVyPUGuN|chdk1? NYTkboQxW0GQR1XS
L-540 NGnCcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTrTWM2OD1zLkO3JI5O MojkV2FPT0WU
CAS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XzVWlEPTB;MT6zO{BvVQ>? NH[3dI9USU6JRWK=
PF-382 M3;XSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvhZnRKSzVyPUGuOFchdk1? MoC5V2FPT0WU
LS-411N M{TKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLKU5VKSzVyPUGuOVMhdk1? M3;3enNCVkeHUh?=
NCI-H69 NGjDbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzNTWM2OD1zLkW0JI5O M13RRnNCVkeHUh?=
NB12 Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwNU[gcm0> MkGxV2FPT0WU
HEL MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPRV2FKSzVyPUGuOlEhdk1? M1jH[nNCVkeHUh?=
GCIY MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjjUW54UUN3ME2xMlYzKG6P MUjTRW5ITVJ?
EHEB NHrpZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFwNkegcm0> MXrTRW5ITVJ?
TGBC1TKB MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLDSng1UUN3ME2xMlcyKG6P M{\OR3NCVkeHUh?=
KURAMOCHI MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3iTWM2OD1zLkeyJI5O M1PVe3NCVkeHUh?=
U-266 NXXZbmxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljZTWM2OD1zLke2JI5O M{HyZXNCVkeHUh?=
LC4-1 NI[5WVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFwN{mgcm0> NFfHcYxUSU6JRWK=
NCI-H2126 NH7me3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTFwODDuUS=> NFT0Z4ZUSU6JRWK=
NCI-H1092 NU\YfodJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLxTWM2OD1zLkigcm0> MWXTRW5ITVJ?
GB-1 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTFwOEGgcm0> NYfW[5ZGW0GQR1XS
MV-4-11 M4\5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL6TWM2OD1zLkiyJI5O NGfWXHlUSU6JRWK=
Becker M2niTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwOEOgcm0> M1frN3NCVkeHUh?=
MPP-89 NEfqTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjie4hKSzVyPUGuPFkhdk1? NWLXZlI4W0GQR1XS
BE-13 NXf6[IZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17NbGlEPTB;MT65N{BvVQ>? NITXRodUSU6JRWK=
697 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLzc5ZKSzVyPUGuPVkhdk1? M{jBUnNCVkeHUh?=
NKM-1 M{\memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M175UmlEPTB;MjDuUS=> MnPZV2FPT0WU
NB13 NGHTZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjKUIN6UUN3ME2yJI5O M2DSWXNCVkeHUh?=
LS-123 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTLTWM2OD1{LkCyJI5O MkP1V2FPT0WU
NB17 NHTNS|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJwMESgcm0> M{jQUXNCVkeHUh?=
LAN-6 M4ntRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\mU2lEPTB;Mj6wOUBvVQ>? NEfKOo5USU6JRWK=
EW-24 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrUTWM2OD1{LkC4JI5O MkWwV2FPT0WU
NOS-1 MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLR[XVKSzVyPUKuNVEhdk1? MY\TRW5ITVJ?
BL-70 NUfL[4V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfOTWM2OD1{LkGyJI5O MV;TRW5ITVJ?
GT3TKB MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rEdGlEPTB;Mj6xNkBvVQ>? MkPUV2FPT0WU
HH MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTNSoFKSzVyPUKuNVMhdk1? MojrV2FPT0WU
KE-37 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnizTWM2OD1{LkGzJI5O M{XkUXNCVkeHUh?=
MOLT-4 Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33L[GlEPTB;Mj6xN{BvVQ>? M1fY[3NCVkeHUh?=
EKVX NFjFc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJwMUSgcm0> NYfQfYJyW0GQR1XS
KGN NXf4dWtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvmTWM2OD1{LkG1JI5O Mkj3V2FPT0WU
ES4 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHGOYlKSzVyPUKuNVYhdk1? NWnoZWw{W0GQR1XS
SJSA-1 NGj5[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj1TWM2OD1{LkKxJI5O NYntXZQ5W0GQR1XS
KMOE-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkezTWM2OD1{LkKzJI5O MUDTRW5ITVJ?
NB5 NX\sT3Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7FTWM2OD1{LkK3JI5O NVy1bYlDW0GQR1XS
BC-1 NVP6UFN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJwM{Ggcm0> NF70d|NUSU6JRWK=
NB10 NEXlSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPKOmdwUUN3ME2yMlMzKG6P NHnNOINUSU6JRWK=
RPMI-8226 NI\aW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfET4x[UUN3ME2yMlM2KG6P NHTz[VBUSU6JRWK=
SCC-3 NYrjb4hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1La[GlEPTB;Mj6zO{BvVQ>? MlXkV2FPT0WU
ARH-77 NEWzTlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHxTWM2OD1{LkO4JI5O MknQV2FPT0WU
NCI-H748 NWfT[Jg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJwM{mgcm0> M{\LeXNCVkeHUh?=
KU812 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn1cJVKSzVyPUKuOFIhdk1? M{PLdXNCVkeHUh?=
NCI-H64 NH3KWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJwNESgcm0> MkfaV2FPT0WU
NB69 NHuzOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHjSJlKSzVyPUKuOFYhdk1? MofBV2FPT0WU
KNS-81-FD M4rYdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrRTWM2OD1{LkS4JI5O MYjTRW5ITVJ?
LB1047-RCC NILtSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHBW|JXUUN3ME2yMlU4KG6P M{\obXNCVkeHUh?=
EB-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC5NpZzUUN3ME2yMlY3KG6P MXnTRW5ITVJ?
Mo-T NGLxTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJwN{Sgcm0> MVXTRW5ITVJ?
EW-16 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPNZphKSzVyPUKuO|Uhdk1? NULKfZZXW0GQR1XS
CTV-1 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW2TWM2OD1{Lkigcm0> MVHTRW5ITVJ?
ETK-1 NECxU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJwOESgcm0> MWDTRW5ITVJ?
C2BBe1 NH\B[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXqe|FrUUN3ME2yMlg6KG6P NEDuZWRUSU6JRWK=
MOLT-16 M1\GR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LJbWlEPTB;Mj64PUBvVQ>? MXPTRW5ITVJ?
SW954 M2PRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJwOTDuUS=> NWS0dpR4W0GQR1XS
HT NIPsT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTNwMEKgcm0> M1PMVnNCVkeHUh?=
KARPAS-299 NVvHdIpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7xN5ppUUN3ME2zMlA3KG6P MVHTRW5ITVJ?
MONO-MAC-6 NV;hTo52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq4TWM2OD1|LkGgcm0> NUCxUXJNW0GQR1XS
CGTH-W-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTNwMTDuUS=> NHPQWppUSU6JRWK=
SK-PN-DW MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;GbG1KSzVyPUOuNVQhdk1? NVnXNFlsW0GQR1XS
CW-2 MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jhd2lEPTB;Mz6yNUBvVQ>? M1HjdnNCVkeHUh?=
SK-N-DZ MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTNwMk[gcm0> NWfO[2xNW0GQR1XS
NEC8 NFPlbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPnTWM2OD1|LkO1JI5O Mk\uV2FPT0WU
LB996-RCC NIPRTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17MVWlEPTB;Mz60JI5O NFnKWWJUSU6JRWK=
DB NYrNO|BUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mke1TWM2OD1|LkSxJI5O NXzFRXJWW0GQR1XS
TE-15 NGrKVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HGfmlEPTB;Mz60N{BvVQ>? MkfVV2FPT0WU
COR-L88 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTNwNEegcm0> M4n5dHNCVkeHUh?=
LAMA-84 M3jUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTNwNEmgcm0> M{PxbnNCVkeHUh?=
MEG-01 MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\BTWM2OD1|LkS5JI5O NYLIUnpTW0GQR1XS
LOXIMVI MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi1TWM2OD1|LkWgcm0> Mkj6V2FPT0WU
RPMI-8402 M1;RdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[xTWM2OD1|LkWgcm0> MXXTRW5ITVJ?
KARPAS-45 M{H1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf6TWM2OD1|LkW0JI5O MnfkV2FPT0WU
HCC1187 NEPCRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TjVmlEPTB;Mz61OEBvVQ>? MX3TRW5ITVJ?
MZ1-PC Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTNwNUSgcm0> MmH2V2FPT0WU
no-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD1TWM2OD1|LkW1JI5O M{HESnNCVkeHUh?=
EVSA-T M3m4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDHTWM2OD1|Lk[gcm0> M{TPVXNCVkeHUh?=
DJM-1 NVTaT2ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTNwNkOgcm0> MWHTRW5ITVJ?
COLO-684 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTNwNk[gcm0> MmP2V2FPT0WU
NMC-G1 MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTNwNkigcm0> NWPMcHBWW0GQR1XS
LC-1F Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTNwN{Sgcm0> NWDmNphLW0GQR1XS
RL95-2 MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fu[GlEPTB;Mz63PUBvVQ>? M{PpUHNCVkeHUh?=
COLO-320-HSR NEnhPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne4TWM2OD1|LkmyJI5O MlzxV2FPT0WU
RCC10RGB MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\ZTWM2OD1|LkmzJI5O MlzEV2FPT0WU
HD-MY-Z M1K1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDoVYhKSzVyPUOuPVMhdk1? MVXTRW5ITVJ?
NCI-H2141 M3yzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTRwMEWgcm0> M{fDNHNCVkeHUh?=
K-562 MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[1OVNKSzVyPUSuNVIhdk1? MVrTRW5ITVJ?
NCI-H1648 NHK5[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDKdGh1UUN3ME20MlE{KG6P MonPV2FPT0WU
OMC-1 NW\ROHlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGye3hDUUN3ME20MlE5KG6P Mkn2V2FPT0WU
LB647-SCLC MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfvVmxUUUN3ME20MlIzKG6P NEjROGlUSU6JRWK=
TE-12 M4nSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvDTXNZUUN3ME20MlI2KG6P M3L0SXNCVkeHUh?=
NOMO-1 M4TtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGGxN|hKSzVyPUSuN|Mhdk1? NUXFeoRuW0GQR1XS
Raji NGC2b|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTRwNE[gcm0> M4S4V3NCVkeHUh?=
NALM-6 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fiT2lEPTB;ND60PUBvVQ>? MoDrV2FPT0WU
HL-60 NIL0cGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPyZoZsUUN3ME20MlY4KG6P NX3KdIY4W0GQR1XS
IST-SL1 M{e3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnOzTWM2OD12Lk[4JI5O MX3TRW5ITVJ?
MHH-PREB-1 NGnpW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHDbpBwUUN3ME20Mlg3KG6P NGPa[VhUSU6JRWK=
MHH-NB-11 M{TVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTRwOUGgcm0> NF;FUoZUSU6JRWK=
JiyoyeP-2003 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjTOHlIUUN3ME21JI5O NFrKfVhUSU6JRWK=
SBC-1 M{DIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Hjd2lEPTB;NT6wNUBvVQ>? MmPtV2FPT0WU
CHP-126 Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTVwME[gcm0> M4[5XHNCVkeHUh?=
LU-139 M2i4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XTT2lEPTB;NT6xN{BvVQ>? NFzIR49USU6JRWK=
NCI-SNU-5 M2HvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTQcZBvUUN3ME21MlE4KG6P M1j3RXNCVkeHUh?=
SW962 M{\5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nyb2lEPTB;NT6yNUBvVQ>? NHTlbVdUSU6JRWK=
EW-1 NVLoeG1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;6em9KSzVyPUWuN|Ehdk1? NWnCemZoW0GQR1XS
NCI-H1417 M{\DVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT5c29KSzVyPUWuOVEhdk1? NUPkR2tFW0GQR1XS
LU-65 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTVwOESgcm0> NEnDcmpUSU6JRWK=
D-502MG M{G5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELNfYJKSzVyPU[uN|chdk1? NV7IV5VjW0GQR1XS
BC-3 NInNS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTZwNkGgcm0> NHe0fFVUSU6JRWK=
GDM-1 MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe0VHRKSzVyPU[uO|chdk1? NVexcnFwW0GQR1XS
NCI-H2196 M37NTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;KTWM2OD14Lkigcm0> NEfYTYtUSU6JRWK=
NB1 NHzDNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H5cGlEPTB;Nj64PEBvVQ>? NF3wc2tUSU6JRWK=
NCI-H345 M1KzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3kU29KSzVyPUeuNkBvVQ>? M1OyenNCVkeHUh?=
SU-DHL-1 M1nnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTdwMkSgcm0> Mo\1V2FPT0WU
JVM-2 NEWxPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvTPFFiUUN3ME23MlI5KG6P NXPuW2VkW0GQR1XS
LU-134-A NWftUlQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TQN2lEPTB;Nz6zPUBvVQ>? NUHEco9wW0GQR1XS
NCI-H1694 NFnqPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTsfYVbUUN3ME23MlU5KG6P MnPwV2FPT0WU
NCI-SNU-16 NHXvRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrsfo4{UUN3ME23MlY2KG6P M4m1T3NCVkeHUh?=
L-363 NYrtdHB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\GNodnUUN3ME23Mlchdk1? M2LzTnNCVkeHUh?=
KG-1 Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTdwOUSgcm0> MorzV2FPT0WU
MN-60 MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRThwMUSgcm0> NGjGe2ZUSU6JRWK=
NB6 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjMNVN6UUN3ME24MlQ5KG6P NFPuTZJUSU6JRWK=
MLMA NV[5TpRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRThwOEWgcm0> NGDzOo9USU6JRWK=
ATN-1 NVTYcIdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\ucZRKSzVyPUiuPFkhdk1? Mn;kV2FPT0WU
SK-NEP-1 M3XFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TabmlEPTB;OT6wNUBvVQ>? MYDTRW5ITVJ?
DMS-114 MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH5TWM2OD17Lk[yJI5O M{nMbXNCVkeHUh?=
CTB-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULMS5QxUUN3ME25MlY4KG6P MYfTRW5ITVJ?
NCI-H2081 NVSy[I5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrjRndwUUN3ME2xNE4xQSCwTR?= NXHzbYxKW0GQR1XS
ES5 MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvmcnlKSzVyPUGwMlM5KG6P NXrqUXN3W0GQR1XS
HCC1599 MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfNTWM2OD1zMT65NUBvVQ>? NGDvR5hUSU6JRWK=
NCI-H23 M1;UXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF{LkGyJI5O NIXTSIJUSU6JRWK=
NCI-H1581 M2iyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7NRYIxUUN3ME2xNk4zQCCwTR?= MmrZV2FPT0WU
JVM-3 NVHyeGVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF{Lkm5JI5O MUTTRW5ITVJ?
NCI-SNU-1 M3W3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTF|LkG5JI5O M2LHTXNCVkeHUh?=
NB7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITIU5NKSzVyPUG1MlkzKG6P M3zpPXNCVkeHUh?=
JAR NEfFbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq2[XFKSzVyPUG2MlE{KG6P MVTTRW5ITVJ?
TGW NWPtbWU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTJTWM2OD1zNj60PEBvVQ>? M3OxSnNCVkeHUh?=
U-87-MG NF3lbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTCS25KSzVyPUG2Mlc3KG6P MkDUV2FPT0WU
NCI-H1436 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P5W2lEPTB;MUeuNFEhdk1? MYHTRW5ITVJ?
GOTO NUm3dlNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7kUYZLUUN3ME2xO{4xPiCwTR?= NFi5fllUSU6JRWK=
COLO-800 MnzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W2NmlEPTB;MUeuOlQhdk1? MknJV2FPT0WU
MFM-223 NHHQ[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF5LkmxJI5O M4\jZXNCVkeHUh?=
EW-18 MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe5cXpKSzVyPUG3Mlk3KG6P MnrYV2FPT0WU
NB14 MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF5Lkm4JI5O MoryV2FPT0WU
EB2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXLTWM2OD1zOD6wPEBvVQ>? MU\TRW5ITVJ?
EoL-1- MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvTWHppUUN3ME2xPE4{OSCwTR?= NW\wXmVkW0GQR1XS
NCCIT NIPMOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF6LkO2JI5O M1XhfXNCVkeHUh?=
DG-75 Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF6Lk[xJI5O MW\TRW5ITVJ?
HCC2218 Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLETWM2OD1zOT61JI5O MXnTRW5ITVJ?
TE-6 NXLYPXozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJyLkC4JI5O NYnuVW9VW0GQR1XS
SF539 M2fCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJyLk[3JI5O MkjjV2FPT0WU
NCI-H446 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvmemNKSzVyPUKxMlE5KG6P MoC1V2FPT0WU
IST-MES1 MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LrXmlEPTB;MkKuO|chdk1? NWL1fHhXW0GQR1XS
NCI-H82 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPZTWM2OD1{Mz6wNkBvVQ>? NG\QOYZUSU6JRWK=
HCC2157 NYn3R3pET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL4SXlCUUN3ME2yN{4yOyCwTR?= MV\TRW5ITVJ?
EW-12 MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnNPYNKSzVyPUKzMlE4KG6P MmDoV2FPT0WU
SIMA M4PIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTJUlljUUN3ME2yN{4{QCCwTR?= MlvpV2FPT0WU
DOHH-2 MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDpW2IzUUN3ME2yN{41PSCwTR?= NFnWTmZUSU6JRWK=
IM-9 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnNTWM2OD1{Mz61OEBvVQ>? MUjTRW5ITVJ?
EC-GI-10 MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XXS2lEPTB;MkSuNlMhdk1? M1rjXnNCVkeHUh?=
HDLM-2 M{K1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrVNo92UUN3ME2yOE42PCCwTR?= MXXTRW5ITVJ?
LS-1034 NUna[|hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJ3Lke1JI5O NXnC[nV[W0GQR1XS
REH NVjDNHdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzTUmxKSzVyPUK2MlQyKG6P NG\sbWdUSU6JRWK=
LU-165 MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\6S5ZKSzVyPUK2MlczKG6P MUXTRW5ITVJ?
NH-12 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrrTWM2OD1{Nz62O{BvVQ>? NWS4dY1CW0GQR1XS
WSU-NHL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJ6LkO5JI5O NF3MbmhUSU6JRWK=
ECC4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDUV2p6UUN3ME2yPE44QSCwTR?= MV7TRW5ITVJ?
OCI-AML2 Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTJeVNZUUN3ME2yPU43QSCwTR?= Mn3wV2FPT0WU
EW-3 NIP3c45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;6[mpKSzVyPUOwMlU6KG6P M2nmOXNCVkeHUh?=
NCI-H526 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nzcmlEPTB;M{KuOVQhdk1? MVrTRW5ITVJ?
NCI-H719 NIXVXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ToXWlEPTB;M{SuN|Ehdk1? NWXmc2VFW0GQR1XS
KARPAS-422 NHnmZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTN3LkC0JI5O MVfTRW5ITVJ?
SK-MEL-1 MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjxV4w6UUN3ME2zOU4yPyCwTR?= NHfJ[YtUSU6JRWK=
ES3 MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTN3LkG5JI5O MkXuV2FPT0WU
UACC-812 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DseGlEPTB;M{WuOFQhdk1? MkT5V2FPT0WU
C8166 NIX1ZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTN3Lkegcm0> MlHYV2FPT0WU
MDA-MB-134-VI NYjPNWtCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW5XIFKSzVyPUO1Mlg4KG6P MVrTRW5ITVJ?
D-283MED M{HCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\NU5lVUUN3ME2zO{44QSCwTR?= NWjK[YxQW0GQR1XS
SHP-77 NVHVfZA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTN6LkCzJI5O MnHMV2FPT0WU
NCI-H2227 NYn5NFRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTRyLkS5JI5O M3zZNnNCVkeHUh?=
SKM-1 NV;Ybo5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:4bI1xUUN3ME20Nk43OyCwTR?= NYf5SlNGW0GQR1XS
L-428 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTR|Lki2JI5O MUnTRW5ITVJ?
RPMI-6666 MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTR3Lki5JI5O M17DOnNCVkeHUh?=
NCI-H716 NF7LVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjqSXhKSzVyPUS4MlgyKG6P NH;VPHpUSU6JRWK=
DMS-79 NF71ZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDkT5cyUUN3ME21NE44OSCwTR?= NUDvOJA{W0GQR1XS
RS4-11 M1fDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTVyLki4JI5O NUKwcplnW0GQR1XS
NCI-H720 NIq0Z3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPnTWM2OD13MT6xNUBvVQ>? NIXiUHBUSU6JRWK=
MC-CAR Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HxOGlEPTB;NUGuOVIhdk1? M1;qOnNCVkeHUh?=
TALL-1 M2TqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHRdJBxUUN3ME21N{46OSCwTR?= M1PG[nNCVkeHUh?=
NCI-N87 NEn3eYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTmTWM2OD13ND6xPEBvVQ>? MnXUV2FPT0WU
P30-OHK M2\QVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn6TWM2OD13ND62NUBvVQ>? M4exd3NCVkeHUh?=
LP-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7TTWM2OD14MT6yPEBvVQ>? MVPTRW5ITVJ?
YT MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi5N5BKSzVyPU[xMlghdk1? NVHBbGpGW0GQR1XS
MRK-nu-1 M1LGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDie4NXUUN3ME22NU45OiCwTR?= NHjiSYRUSU6JRWK=
BT-474 NYC0bmN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDQTWM2OD14NTDuUS=> M1rkcnNCVkeHUh?=
NCI-H322M Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[3TWM2OD14Nj6xNUBvVQ>? MVXTRW5ITVJ?
NCI-H128 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTDN45KSzVyPUe0Mlc4KG6P MmryV2FPT0WU
KMS-12-PE M2fQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLtUFFKSzVyPUe2MlI1KG6P NVzZS25xW0GQR1XS
KP-N-YS MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPITWM2OD15Nj63OEBvVQ>? M{jY[XNCVkeHUh?=
ALL-PO NGjteldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\zTWM2OD15Nz62OkBvVQ>? Mo\lV2FPT0WU
EW-13 NXjndFVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX2xPGROUUN3ME23O{44PiCwTR?= NGnoe5RUSU6JRWK=
EW-11 Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnpTWM2OD15OD61NkBvVQ>? MkPhV2FPT0WU
SK-N-FI NVfRZmpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PycWlEPTB;OECuNkBvVQ>? M4TF[nNCVkeHUh?=
CAL-148 NUjYPHFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorPTWM2OD16MT64OEBvVQ>? NH;5RphUSU6JRWK=
RL MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LnUmlEPTB;OE[uNFkhdk1? NET3TJpUSU6JRWK=
AM-38 NEHKVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2T6c2lEPTB;OEiuNFghdk1? NGDDW4JUSU6JRWK=
RH-1 NVjr[G96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTGTWM2OD17OT64OUBvVQ>? MWLTRW5ITVJ?
NCI-H1770 M2XUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XVcGlEPTB;MUCyMlQ6KG6P NVnvWJNlW0GQR1XS
SIG-M5 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFyNT6wOkBvVQ>? NUfEcXFmW0GQR1XS
GR-ST NWDUWVFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFzMz6zOEBvVQ>? NE\q[29USU6JRWK=
ST486 M4\FNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;1dlBKSzVyPUGxOE4xPiCwTR?= NX\ROGdsW0GQR1XS
NCI-H1650 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf2SZc5UUN3ME2xNVUvOjlibl2= MonnV2FPT0WU
MHH-CALL-2 MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PaPWlEPTB;MUG1Mlchdk1? MX\TRW5ITVJ?
BV-173 MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGyTWM2OD1zMkKuO|Ehdk1? M33QO3NCVkeHUh?=
MC116 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF2OD64OUBvVQ>? M1y1NHNCVkeHUh?=
NCI-H524 NI\1UIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF3OT6xJI5O NHXJV4FUSU6JRWK=
SCLC-21H NHK0RlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPGTWM2OD1zNUmuOFEhdk1? MXnTRW5ITVJ?
NCI-H1304 NIm4d2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUW4UYN[UUN3ME2xOlkvOjFibl2= MXrTRW5ITVJ?
NCI-H510A M3THbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP6TWM2OD1zOEWuN|chdk1? NEDEc2lUSU6JRWK=
NCI-H209 M1jP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF7Nj61NkBvVQ>? NUL0NHpTW0GQR1XS
KM-H2 NF20[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPJTWM2OD1zOUeuNFUhdk1? M3zv[3NCVkeHUh?=
NCI-H1395 M33Bb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDzNIF4UUN3ME2yNVAvOTNibl2= MnexV2FPT0WU
NCI-H1155 MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn76TWM2OD1{M{CuN|Ihdk1? NXPOb4dJW0GQR1XS
COR-L279 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF2zfoRKSzVyPUK1Nk4yPyCwTR?= NFvZTHFUSU6JRWK=
NCI-H1299 Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnXTZVuUUN3ME2yOlEvPzFibl2= MUnTRW5ITVJ?
EW-22 M{HrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ4Mz63OUBvVQ>? MlH5V2FPT0WU
SK-MEL-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJ6MT65JI5O NIrnbFFUSU6JRWK=
KASUMI-1 Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJ6Mz6wOUBvVQ>? NH7od3RUSU6JRWK=
NCI-H187 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJ6Nz6wPEBvVQ>? MoS5V2FPT0WU
NCI-H2171 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GwV2lEPTB;Mki4MlkzKG6P MkLiV2FPT0WU
LNCaP-Clone-FGC NUTwe21UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfCRmluUUN3ME2yPVUvOjZibl2= M1TzenNCVkeHUh?=
NCI-H1522 M{LSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK2OFFnUUN3ME2zNFcvODVibl2= MWPTRW5ITVJ?
SCH M1PIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTN{Mj6yNkBvVQ>? M3;DbnNCVkeHUh?=
THP-1 NVW1OG9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2OxRWlEPTB;M{KyMlYhdk1? NXjlSY9uW0GQR1XS
SNU-C1 M{PRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN4Mj6wPUBvVQ>? NXLweFYzW0GQR1XS
CA46 NVP5S|h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTN5Mz62N{BvVQ>? M1rRR3NCVkeHUh?=
NCI-H1963 NVi3boc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTN6Nj6xPUBvVQ>? MlzUV2FPT0WU
DEL NEn2WIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV23cY1XUUN3ME2zPVEvOjdibl2= NEfT[YhUSU6JRWK=
TUR NVzCcoV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTN7Nj62NUBvVQ>? MUTTRW5ITVJ?
NCI-H226 NWTTfoc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HSXGlEPTB;NECzMlI{KG6P MXPTRW5ITVJ?
COLO-668 M2DFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzZN3pZUUN3ME20NFMvPTdibl2= M4H0SXNCVkeHUh?=
CPC-N MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnVTWM2OD12MEOuO|chdk1? NGLjUFRUSU6JRWK=
NCI-H889 NIfuRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7Ue49KSzVyPUS2NU46OiCwTR?= MUnTRW5ITVJ?
J-RT3-T3-5 Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTV|Mj61O{BvVQ>? NVLVSJZ3W0GQR1XS
MSTO-211H M3naUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\4UWlEPTB;NUe0MlI3KG6P M1npeXNCVkeHUh?=
SCC-15 M2jzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\LTWM2OD14NkeuOFchdk1? NWC3bIpkW0GQR1XS
SUP-T1 NEH4OXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorJTWM2OD14OE[uNFQhdk1? NHnFZYpUSU6JRWK=
DMS-153 NVzGeJRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTd2Nj64N{BvVQ>? NXHF[nUyW0GQR1XS
MS-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H0ZmlEPTB;N{W5MlQzKG6P NUjSPVVxW0GQR1XS
TC-YIK M3z6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTd6MT6wNUBvVQ>? NGe3OZNUSU6JRWK=
RPMI-8866 M4HBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFyME[uNlgh|ryP MWHTRW5ITVJ?
KY821 M17aOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\scZRKSzVyPUGwN|YvODRizszN M4rhPXNCVkeHUh?=
P31-FUJ MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPtbolKSzVyPUGxNVIvPzVizszN NF3tO29USU6JRWK=
COLO-824 NVnsZ5hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDjTllOUUN3ME2xNlYyNjd6IN88US=> NXzOdok{W0GQR1XS
U-698-M M{nRSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj6TpEyUUN3ME2yNlYzNjF3IN88US=> NHrtZ|BUSU6JRWK=
TE-441-T MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHUe2tKSzVyPUK1NlEvPyEQvF2= MYDTRW5ITVJ?
IMR-5 NVvufWF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon3TWM2OD1|NEC5MlYzKM7:TR?= Mk\pV2FPT0WU
NCI-H1838 M1\oR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX4TWM2OD12MUi2MlMzKM7:TR?= NXnXNlN7W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID